1/6/2017

1

Welcome & Introductions

Dr. Richardson’s slides are available for download at

www.LLS.org/programs

1

Emerging Therapies for Multiple Myeloma:

2016 ASH® Annual Meeting Highlights

Friday, January 6, 2017

Emerging Therapies for Multiple Myeloma: 2016 ASH® Annual

Meeting Highlights

Paul G. Richardson, MD

RJ Corman Professor of Medicine

Harvard Medical School

Clinical Program Leader, Director of Clinical Research

Jerome Lipper Multiple Myeloma Center

Dana-Farber Cancer Institute

Boston, Massachusetts

2

1/6/2017

2

Friday, January 6, 2017

Disclosure

Paul G. Richardson, MD, has affiliations with Bristol

Myers Squibb, Celgene, Janssen, Novartis, Takeda,

Triphase (Advisory Committee).

3

MULTIPLE MYELOMA

…not just one disease!

• Risk stratification, recognition of clonal heterogeneity

• Individualization of treatment, advent of novel therapies

3 decades

Drach J, ASH 2012

Morgan et al. Nat Rev Cancer 2012;12:335-348 4

1/6/2017

3

Importance of Interaction Between Plasma Cells

and Bone Marrow for Development of Myeloma

Palumbo A. and Anderson KC. New Engl J Med 2011;364:1046-1060 5

Natural History of Multiple Myeloma:

All Pts Experience Relapse

MGUS or

smoldering

myeloma

Asymptomatic Symptomatic

ACTIVE

MYELOMA

M P

rote

in (

g/L

)

20

50

100

1. RELAPSE

2. RELAPSE

REFRACTORY

RELAPSE

First-line therapy

Plateau

remission

Second-line Third-line

Durie BGM. Concise review of the disease and treatment options. Multiple myeloma; 2008/2009

Available from: http://myeloma.org/pdfs/cr08-eng_f1web.pdf 6

1/6/2017

4

Integration of Novel Agents Into

Myeloma Management

Bortezomib, Lenalidomide, Thalidomide, Bortezomib/Doxil,

Carfilzomib, Pomalidomide, Panobinostat, Daratumumab,

Elotuzumab, Ixazomib, glycosylated Melphalan

Target MM in the BM microenvironment to overcome

conventional drug resistance in vitro and in vivo

Effective in relapsed/refractory, relapsed, induction,

consolidation, and maintenance therapy

Nineteen FDA approvals in the last 13 years: median survival

prolonged from 3-5 to 7-10 years, with additional prolongation

from maintenance

New approaches needed to treat and prevent relapse

7

Adapted from Kumar et al Leukemia 2014

Multiple Myeloma survival improving with new drugs:

but all patients still relapse after IMiD and PI failure

1960-65

1965-70

1970-75

1975-80

1980-85

1985-90

1990-95

1995-00

2000-05

2005-10

Early Deaths in High Risk

No Plateau

8

1/6/2017

5

Poor survival outcomes for patients with

advanced Relapsed/Refractory MM

• For patients (N = 286) refractory to Bort and relapsed/refractory

or ineligible for immunomodulatory drugsa

– 49% had no response to the first treatment

– Median OS was

12 months for

patients receiving

at least one

treatment, and

3 months for

patients receiving

no treatment

a Lenalidomide and/or thalidomide.

Bort, bortezomib; EFS, event-free survival; OS, overall survival. Kumar SK, et al. Leukemia. 2012;26:149–157. 9

Multiple genetically distinct subclones can

occur in multiple myeloma

• Multiple genetically distinct subclones are present at

diagnosis1–4

– These evolve over time due to selective pressures from treatment and

factors in the microenvironment1,4

– This clonal evolution can result in disease progression and treatment

resistance5

1. Bahlis N et al. Blood 2012;120:927–28

2. Keats JJ et al. Blood 2012;120:1067–76

3. Bianchi G, Ghobrial IM. Curr Cancer Ther Rev 2014;10:70–9

4. Bolli N et al. Nat Commun 2014;5:2997

5. Brioli A et al. Br J Haematol 2014;165:441–54.10

1/6/2017

6

WGS at diagnosis

Courtesy of Nikhil Munshi MD, DFCI11

WGS at relapse

Courtesy of Nikhil Munshi MD, DFCI12

1/6/2017

7

Multimodality targeting of MM in the context of the BM microenvironment

G. Bianchi, PG. Richardson and KC. Anderson, Blood 2015;126:300-31013

Lonial S, Mitsiades CS, Richardson PG. Clin Cancer Res 2011;17:1264-77.

Rational combination strategies

in relapsed, refractory MM

+ MoAbs3rd generation

IMiDs (POM)2nd, 3rd generation

PI’s (CFLZ, IXA)

14

1/6/2017

8

Options in Relapse –

NCCN Guidelines 2016

15

New Directions:

Key Targets in MM

Excess Protein Production:

• Target Protein degradation

• Synergistic Strategies with next

generation novel agents

Genomic abnormalities:

• Target and overcome mutations

• Critical Role of Combination Therapy

Immune Suppression:

• Restore anti-MM immunity

• Memory (thru vaccines, cellular therapy)16

1/6/2017

9

0

20

40

60

80

100

0 10 20Bz, nM

Gro

wth

(%

)

0 mM

5 mM

Len

0

10

20

30

40

50

Cell

Death

(%

)

Bz-Resistant Patient Cells

Mitsiades N, et al. Blood. 2002;99(12):4525-4530

Hideshima T, et al. 2003

Rationale: Preclinical Combination of Lenalidomide (Len) + Bortezomib (Bz)

Combination therapy now standard of care

17

J Clin Oncol 2009 Dec 1;27(34):5713-9.; Blood 2010 Aug 5;116(5):679-86.; Blood 2014 Mar 6;123(10):1461-9. 18

1/6/2017

10

ASPIRE Study:

Carfilzomib + lenalidomide + dexamethasone

Primary endpoint – PFS

1.0

0.8

0.6

0.4

0.2

0.0

Pro

po

rtio

n S

urv

ivin

g

Wit

ho

ut

Pro

gre

ss

ion

KRd

Rd

0 6 12 18 24 30 36 42 48

Months Since Randomization

KRd Rd

(n=396) (n=396)

Median PFS, mo 26.3 17.6

HR (KRd/Rd) (95% CI) 0.69 (0.57–0.83)

P value (one-sided) 0.0001

KRd-treated patients had a 31% reduction in the risk of disease

progression or death in comparison with Rd

Stewart AK, et al. N Engl J Med 2015;372:142-52ITT Population (N=792)19

TOURMALINE-MM1

N Engl J Med 2016 374;17 20

1/6/2017

11

TOURMALINE-MM1Phase 3 study of weekly oral ixazomib plus lenalidomide-dexamethasone

Final PFS analysis: Significantly improved PFS with IRd vs Rd

Number of pts at risk:

IRd

Rd

360 345 332 315 298 283 270 248 233 224 206 182 145 119 111 95 72 58 44 34 26 14 9 1 0

362 340 325 308 288 274 254 237 218 208 188 157 130 101 85 71 58 46 31 22 15 5 3 0 0

1.0

0.8

0.6

0.4

0.2

0.0

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Pro

ba

bil

ity o

f p

rog

res

sio

n-f

ree

su

rviv

al

Time from randomization (mos)

Log-rank test p=0.01

Hazard ratio (95% CI): 0.74 (0.59, 0.94)

Number of events: IRd 129; Rd 157

Median PFS:

IRd 20.6 mos, Rd 14.7 mos

Moreau P. et al, NEJM 2016;374(17):1621-34

Median follow-up:

14.8 mos

14.6 mosRd

IRd

35% longer PFS with IRd vs. Rd

21

Pan-DACi inhibit a broad range of deacetylase enzymes: target both

histone and nonhistone proteins involved in oncogenesis1

Pan-DACi inhibit growth and promote death of MM cells through inhibition of HDAC enzymes:

• Histone proteins, implicated in epigenetic dysregulation, result in activation of tumor suppressor genes2-4

• Nonhistone proteins,promote toxic accumulation of misfolded proteins, lead to cell stress2,5,6,7,8

1. Panobinostat, Novartis; 2014; 2. Atadja P, et al. Cancer Lett. 2009;280:233-241; 3. Mannava S, et al. Blood. 2012;119:1450-1458;

4. Kalushkova A, et al. PloS One. 2010;5:e11483; 5. Catley L, et al. Blood. 2006;108:3441-3449; 6. Glozak MA and Seto E. Oncogene. 2007;26:5420-5432;

7. Hideshima T, et al. Mol Cancer Ther. 2011;10:2034-2042; 8. Hideshima T, et al. Proc Natl Acad Sci USA. 2005;102:8567-8572

Pan-DAC Inhibitors: Mechanism of Action

HDAC

Pan-DACi

NonhistoneHistone

(epigenetic)

Activation of tumor

suppressor genes

(eg p21, p27)

HDAC 1, 2, 3 HDAC 1, 2 HDAC 6

Accumulation of

misfolded

proteins

Histones p53 Tubulin HSP90

Nucleus

Cytoplasm

Aggresome

Cell Death

22

1/6/2017

12

Blood 2013 Oct 3;122(14):2331-7; Lancet Oncol 2014 Oct;15(11):1195-206; Blood 2016 Feb 11;127(6):713-21. 23

100

80

60

40

20

0

PANORAMA 1 Study:

Panobinostat + bortezomib + dexamethasone

Primary endpoint – PFS

• Primary endpoint was met (P < .0001), with clinically relevant

increase in median PFS of 3.9 months for PAN-BTZ-Dex arm

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36

387 288 241 202 171 143 113 89 69 52 44 35 26 18 13 10 5 3 0

381 296 235 185 143 114 89 64 42 32 24 18 12 5 5 3 2 0 0

MonthsNumber of patients at riskPAN-BTZ-Dex

Pbo-BTZ-Dex

Pro

gre

ssio

n-f

ree s

urv

ival P

rob

ab

ilit

y (

%)

Events

Median PFS

(95% CI)

months

HR

(95% CI)P value

PAN-BTZ-Dex 207/38712.0

(10.3, 12.9) 0.63

(0.52-0.76)< .0001

Pbo-BTZ-Dex260/381

8.1

(7.6, 9.2)

PAN-BTZ-Dex

Pbo-BTZ-Dex

San-Miguel J. et al, Lancet Oncol 2014. 24

1/6/2017

13

Richardson PG et al, Blood 2016.

PANORAMA 1 Study:

PFS subgroup analysis –

Prior IMiD + BTZ with ≥ 2 Prior Lines

25

Restoring Immune function:

Immunomodulatory drugs, other

small molecules (e.g. HDACi’s)

Monoclonal antibodies

Checkpoint inhibitors

Vaccines

Cellular therapies

26

1/6/2017

14

Lenalidomide and Pomalidomide in

Myeloma

MM cells

Bone Marrow

Stromal Cells

Dendritic

Cells

IL-6

TNF

IL-1A

IL-2

IFN

CD8+ T

Cells

C

E

Bone Marrow

Vessels

ICAM-1

VEGF

bFGF

D

B

NK Cells

NK-T

Cells

Hideshima et al. Blood 96: 2943, 2000

Davies et al. Blood 98: 210, 2001

Gupta et al. Leukemia 15: 1950, 2001

Mitsiades et al. Blood 99: 4525, 2002

Lentzsch et al Cancer Res 62: 2300, 2002

LeBlanc R et al. Blood 103: 1787, 2004

Hayashi T et al. Brit J Hematol 128: 192, 2005

PKC

NFAT

PI3K

IL-2

CD28

27

Immunomodulatory agents

IMiDs: mechanism of action

Figure adapted from Stewart KA. Science 2014; 343: 256-257.0

Kronke et al, Science, 2014

Lu et al, Science, 201428

1/6/2017

15

Gandhi AK et al. Brit J Haematol, 2013

Model of Lenalidomide and Pomalidomide Co-Stimulation

of T Cells via Degradation of Aiolos and Ikaros

29

Blood 2013 Mar 14;121(11):1961-7.

Blood 2014 Mar 20;123(12):1826-32. 30

1/6/2017

16

Efficacy Results of POMALIDOMIDE + LoDEX in

advanced RR MM (Phase II/III: MM002 & MM003)

3 17

30 24

128

0

10

20

30

40

50

MM-002 MM-003

MR

PR

VGPR

CR/sCR

ORR = 33% ORR = 32%

Perc

en

tag

e r

esp

on

se

MM-002 (n=113)1 MM-003 (n=302)2,3

MM-0021 MM-0032,3

Median follow-up, months 14.2 15.4

Median DoR, months 8.3 7.5

Median PFS, months 4.2 4.0

Median OS, months 16.5 13.1

1.Richardson PG, et al. Blood 2014;123:1826-32.

2. San Miguel J, et al. Lancet Oncology 2013;14:1055-1066.

3. San Miguel et al: ASH 2013; Oral Presentation and Abstract 686.

CR, complete response; DoR, duration of response; LoDEX, low-dose dexamethasone; MR, minimal response;

ORR, overall response rate; OS, overall survival; PFS, progression-free survival; POM, pomalidomide; PR, partial

response; sCR, stringent complete response; VGPR, very good partial response.

31

MM-003 Study: PFS

San Miguel et al. Lancet Oncol 2013;14.(11 ):1055-66.Based on IMWG criteria.32

1/6/2017

17

Monoclonal Antibodies Kill MM Through Multiple Mechanisms

DIRECT EFFECTS INDIRECT EFFECTS

Interferes with survival or

delivers myeloma-killing substances

Labels myeloma cells for killing by complement

Labels myeloma cells for killing by NK cells

Monoclonal antibody

Myeloma cell surface target

Complement

Fc receptor

NK cell toxins

Activates T cells by taking the brakes off

Checkpoint inhibitor

Adapted from Richardson PG, ASH 201233

MAb-Based Therapeutic Targeting of Myeloma

Antibody-dependent

Cellular cytotoxicity

(ADCC)

ADCC

Effector cells:

MM

FcR

Complement-dependent

Cytotoxicity (CDC)

CDC

MM

C1q

C1q

Apoptosis/growth

arrest

via targeting

signaling pathways

MM

• Lucatumumab or Dacetuzumab (CD40)

• Elotuzumab (CS1; SLAMF7)

• Daratumumab, SAR650984, MOR 202 (CD38)

• XmAb5592 (HM1.24)

• huN901-DM1 (CD56)

• nBT062-maytansinoid

(CD138)

• Siltuximab (1339) (IL-6)

• BHQ880 (DKK1)

• RAP-011 (activin A)

• Daratumumab,

SAR650984, MOR 202

(CD38)

• Daratumumab

• SAR650984

(CD38)

Adapted from Tai & Anderson Bone Marrow Research 201134

1/6/2017

18

Elotuzumab: Immunostimulatory

Mechanism of Action

• Elotuzumab is an immunostimulatory monoclonal antibody that recognizes

SLAMF7, a protein highly expressed by myeloma and natural killer cells1

• Elotuzumab causes myeloma cell death via a dual mechanism of action2

1. Hsi ED et al. Clin Cancer Res 2008;14:2775–84; 2. Collins SM et al. Cancer Immunol Immunother 2013;62:1841–9.

ADCC=antibody-dependent cell-mediated cytotoxicity; SLAMF7=signaling lymphocytic activation molecule F7

Directly activating

natural killer cells

A

Tagging for

recognition

(ADCC)

B

EAT-2

Downstream

activating

signaling

cascade

Perforin,

granzyme B

release

Elotuzumab

Natural killer cell

SLAMF7

Myeloma cellMyeloma

cell

Degranulation

Downstream

activating

signaling

cascade

EAT-2SLAMF7

Polarization

Natural killer cell

Granule synthesis

Myeloma

cell death

35

ELOQUENT-2: Primary Analysis

Co-primary endpoint:

ORRE-Ld Ld

%

95% CI

79

74, 83

66

60, 71

1. Lonial S et al. N Engl J Med 2015;373:621–31.

ELOQUENT-2 demonstrated clinical benefits of E-Ld compared

with lenalidomide and dexamethasone (Ld) alone1

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

380 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36No. of patients at risk:

E-Ld

Ld

321

325

303

295

279

249

259

216

232

192

215

173

195

158

178

141

157

123

143

106

128

89

117

72

85

48

59

36

42

21

32

13

12

7

7

2

57%

68%

27%

41%

1-year PFS 2-year PFS

PFS (months)

Pro

bab

ilit

yp

rog

ressio

nfr

ee

1

0

0

0

HR 0.7

(95% CI 0.57, 0.85)

p<0.001

Co-primary endpoint: PFS

From N Engl J Med, Lonial S et al, Elotuzumab therapy for relapsed or refractory multiple myeloma, 373, 621–31.

Copyright © 2015, Massachusetts Medical Society. Reprinted with permission

E-Ld

Ld

36

1/6/2017

19

1.0

0.8

0.6

0.4

0.2

0.0

Pro

ba

bilit

y P

rog

ressio

n F

ree

0.9

0.7

0.5

0.3

0.1

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38

PFS (months)

Elotuzumab in High-Risk Patients

Lonial S et al. J Clin Oncol. 2015;33. Abstract 8508.

ELOQUENT-2 Study ResultsProgression-Free Survival of Patients With del(17p) and t(4;14) Translocation

1.0

0.8

0.6

0.4

0.2

0.0

Pro

ba

bilit

y P

rog

ressio

n F

ree

0.9

0.7

0.5

0.3

0.1

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38

PFS (months)

t(4;14)+del(17p)+

Hazard ratio: 0.65(95% CI, 0.450.94)

Hazard ratio: 0.53(95% CI, 0.290.95)

E-Ld

Ld E-Ld

Ld

37

Elotuzumab + bortezomib + dexamethasone: PFS

EBd (events: 67/77)

Bd (events: 67/75)

EBd Bd

HR 0.76 (70% CI, 0.63–0.91; 95% CI, 0.53–1.08);

stratified log-rank p=0.1256

Median PFS

(95% CI)

9.7 mos

(7.4–12.2)

6.9 mos

(5.1–10.2)

Stratified HR adjusting for prognostic factors

0.62 (70% CI, 0.51–0.77; 95% CI, 0.42–0.92);

p=0.0184

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42

PFS (mos)

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

Number of pts at risk

EBd

Bd

77

75

72

62

62

51

50

38

45

33

35

27

29

22

26

17

23

14

20

12

16

9

14

9

13

7

10

7

6

5

4

3

3

1

2 1 1 1

0 0 0

0

01

33%

40%

11%

18%

1-year PFS 2-year PFS

Pro

bab

ilit

y p

rog

ressio

n f

ree

Palumbo et al. Presented at ASH 2015 (Abstract 510), oral presentation

• EBd-treated pts had a 24% reduction in the risk of disease progression or death

• Stratified by prognostic factors, EBd-treated pts had a 38% reduction

38

1/6/2017

20

Daratumumab: Mechanism of Action

• Human CD38 IgGκ

monoclonal

antibody

• Direct and indirect

anti-myeloma

activity1-5

• Depletes CD38+

immunosuppressiv

e regulatory cells5

• Promotes T-cell

expansion and

activation5

1. Lammerts van Bueren J, et al. Blood. 2014;124:Abstract 3474.

2. Jansen JMH, et al. Blood. 2012;120:Abstract 2974.

3. de Weers M, et al. J Immunol. 2011;186:1840-8.

4. Overdijk MB, et al. MAbs. 2015;7:311-21.

5. Krejcik J, et al. Blood. 2016. Epub ahead of print. 39

N Engl J Med 2015 Sep 24;373(13):1207-19; Lancet 2016 Apr 9;387(10027):1551-60. 40

1/6/2017

21

Synergistic With Other Standard MM Therapies, Including

Bortezomib and Lenalidomide

LEN: 3 mM lenalidomideBORT: 3 nM bortezomibDARA: 10 mg/mL daratumumab

BM-MNC, n = 16

All DARA combinations vs alone, P <0.001.BM-MNC, bone marrow mononuclear cells.

90

0

80

60

50

30

10

BORT+LEN+

DARA

MM

ce

ll l

ys

is (

%)

LEN+

BORT

BORT+

DARA

BORTLEN+

DARA

LENDARACtrl

20

40

70

van der Veer MS, et al. Blood Cancer J. 2011;1(10):e41.41

Palumbo A et al. N Engl J Med. 2016;375:754.42

1/6/2017

22

Updated Efficacy; ASH 2016

ITT, intent to treat.

Note: PFS: ITT population; ORR: response-evaluable population.aKaplan-Meier estimate.bP <0.0001 for DVd versus Vd.

Median (range) follow-up: 13.0 (0-21.3) months

An additional 7% of patients receiving DVd achieved ≥CR with longer follow up

HR: 0.33 (95% CI, 0.26-0.43; P <0.0001)

60%

22%

12-month PFSa

Vd

DVd

Median:

7.1 months

% s

urv

ivin

g w

ith

ou

t p

rog

ressio

n

0

20

40

60

80

100

0 3 6 9 12 15 18 24

247

251

182

215

129

198

73

160

23

91

9

33

0

5

0

1Vd

DVd

No. at riskMonths

21

0

0

0

10

20

30

40

50

60

70

80

90

100

DVd (n = 240) Vd (n = 234)

OR

R,

%

sCR

CR

VGPR

PR

ORR = 84%

ORR = 63%

P <0.0001

35%

19%

7%

34%

19%

8%2%

≥VGPR

62%b

≥CR

26%b

≥VGPR

29%

≥CR

10%

22%

Responses continue to deepen in the DVd group with longer follow-up

43

Conclusions

• PFS benefit continues to be maintained with DVd over time

• DVd is superior to Vd regardless of prior lines of therapy

• Largest magnitude of benefit with DVd is observed in patients with

1 prior line of therapy

• 78% reduction in risk of progression or death

for DVd versus Vd• More patients in DVd achieved deeper responses with longer

follow-up

• Higher CR and MRD-negative rates

• MRD negativity translated into longer PFS• DVd is superior to Vd regardless of cytogenetic risk or time since

last therapy

• No new safety signals were reportedThese data further support the use of this newly approved regimen of DVd

in RRMM, with most benefit in patients with 1 prior line of therapy44

1/6/2017

23

Dimopoulos M et al. N Engl J Med. 2016;375:1319.45

aOn daratumumab dosing days, dexamethasone was administered 20 mg premed on Day 1 and 20 mg on Day 2; RRMM, relapsed or refractory multiple myeloma; ISS, international staging system; R,

lenalidomide; DRd, daratumumab/lenalidomide/dexamethasone; IV, intravenous; qw, once weekly; q2w, every 2 weeks; q4w, every 4 weeks; PD, progressive disease; PO, oral; d, dexamethasone; Rd,

lenalidomide/dexamethasone; TTP, time to progression; MRD, minimal-residual disease.

POLLUX: Study Design

Cycles: 28 days

DRd (n = 286)

Daratumumab 16 mg/kg IV

• Qw in Cycles 1-2, q2w in Cycles 3-6,

then q4w until PD

R 25 mg PO

• Days 1-21 of each cycle until PD

d 40 mg PO

• 40 mg weekly until PD

Rd (n = 283)

R 25 mg PO

• Days 1-21 of each cycle until PD

d 40 mg PO

• 40 mg weekly until PD

Primary endpoint

• PFS

Secondary endpoints

• TTP

• OS

• ORR, VGPR, CR

• MRD

• Time to response

• Duration of response

Key eligibility criteria

• RRMM

• ≥1 prior line of therapy

• Prior lenalidomide

exposure, but not

refractory

• Patients with creatinine

clearance ≥30 mL/min

Multicenter, randomized (1:1), open-label, active-controlled phase 3 study

Stratification factors

• No. prior lines of therapy

• ISS stage at study entry

• Prior lenalidomide

R

A

N

D

O

M

I

Z

E

1:1

Pre-medication for the DRd treatment group consisted of dexamethasone 20 mga,

paracetamol, and an antihistamine

Statistical analyses

• 295 PFS events: 85% power for

7.7 month PFS improvement

• Interim analysis: ~177 PFS

events

46

1/6/2017

24

PFS, progression-free survival; DRd, daratumumab/lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; HR, hazard ratio; CI, confidence interval.

POLLUX: Progression-free Survival

% o

f p

ati

en

ts p

rog

ressio

n f

ree a

nd

aliv

e

0

20

40

60

80

100

0 3 6 9 12 15 18 21

283

286

249

266

206

248

179

232

139

189

36

55

5

8

0

0

Rd

DRd

No. at risk

Months since randomization

Median PFS: 18.4

months

Median PFS: not reached

HR: 0.37 (95% CI, 0.27-0.52); P <0.0001

RdDRd

• DRd patients demonstrated a 63% reduction in the risk of disease progression or death

47

Overall Response Rate a

• Median duration of response: Not reached for DRd vs 17.4 months for Rd

• Median time to response: 1.0 month for DRd vs 1.3 months for Rd

17%

32%

33%

25%

25% 12%

18%

7%

0

10

20

30

40

50

60

70

80

90

100

DRd (n=281) Rd (n=276)

Ove

rall

re

sp

on

se

ra

te, %

sCR

CR

VGPR

PR

≥CR:

19%

≥VGPR:

76%*

≥CR:

43%*

≥VGPR:

44%

*P <0.0001

ORR = 93%

ORR = 76%

P <0.0001

aWhen serum interference was suspected, CR was confirmed using the daratumumab interference reflex assay.48

1/6/2017

25

Updated Efficacy; ASH 2016

HR, hazard ratio; CI, confidence interval; sCR, stringent complete response; PR, partial response.

Note: PFS = ITT population; ORR = response-evaluable population.aKaplan-Meier estimate; bP <0.0001 for DRd vs Rd.

% s

urv

ivin

g w

ith

ou

t p

rog

ressio

n

0

20

40

60

80

100

0 3 6 9 12 18 21 27

283

286

249

266

206

249181

237

159

227

132

194

5

15

0

1Rd

DRd

No. at risk Months

24

0

0

15

48

82

76%

49%

18-month

PFSa

Rd

DRd

Median:

17.5 months

HR: 0.37 (95% CI, 0.28-0.50; P <0.0001)

OR

R, %

15

32

32

25

2312

23

8

0

10

20

30

40

50

60

70

80

90

100

DRd (n = 281) Rd (n = 276)

sCR

CR

VGPR

PR

ORR = 93%

ORR = 76%

P <0.0001

≥VGPR:

78%b

≥CR:

46%b

≥VGPR:

45%

≥CR:

20%

• Median (range) follow-up: 17.3 (0-24.5) months

Median:

not reached

Responses continue to deepen in the DRd group with longer follow-up

49

MRD-negative Rate; ASH 016

31.8

8.8

24.8

5.7

11.9

2.5

0

5

10

15

20

25

30

35

DRd Rd DRd Rd DRd Rd

10-4 10-5 10-6

MR

D-n

eg

ative

ra

te, %

* * *

Sensitivity

threshold 10–4 10–5 10–6

Intent-to-treat population.

P values are calculated using likelihood-ratio chi-square test.

MRD-negative rates were >3-fold higher at all thresholds

*P <0.0001.

4.4X 4.8X3.6X

50

1/6/2017

26

OS; ASH 2016

Intent-to-treat population.

Median OS was not reached; results did not cross the prespecified stopping boundary.

Rd

DRd

HR: 0.63 (95% CI: 0.42-0.95)

OS eventsa

– 40 (14%) in DRd

– 56 (20%) in Rd

Curves are beginning to separate, but OS data are immature

% s

urv

ivin

g p

ati

en

ts

0

20

40

60

80

100

0 3 6 9 12 18 21 27

283

286

272

277

255

271

249

266

236

260

215

232

18

210

1

Rd

DRd

No. at riskMonths

24

0

0

15

94

102

51

Conclusions

• Daratumumab-Rd significantly improved PFS in

comparison with Rd alone

• DRd was associated with a 63% reduction in the

risk of progression or death

• Treatment benefit of DRd versus Rd was consistent

across subgroups

• DRd doubled CR/sCR rates and quadrupled MRD-

negative rates

• DRd has a manageable safety profile consistent with

the known safety profile of daratumumab or Rd alone

Daratumumab combined with Rd potentially represents a new

standard of care for myeloma patients after ≥1 prior treatment

52

1/6/2017

27

Lenalidomide-based Studies

POLLUX

DRd vs Rd

PFS HR

(95% CI)

0.37

(0.27-0.52)

ORR 93%

≥VGPR 76%

≥CR 43%

Duration of

response,

mo

NE

OS HR

(95% CI)

0.64

(0.40-1.01)

1. Stewart AK, et al. N Engl J Med. 2015;372(2):142-152.

2. Lonial S, et al. N Engl J Med. 2015;373(7):621-631.

3. Dimopoulos MA, et al. Blood. 2015;126(23):Abstract 28.

4. Moreau P, et al. N Engl J Med. 2016;374(17):1621-1634.

ASPIRE

KRd vs Rd1

ELOQUENT-2

Elo-Rd vs Rd2,3

TOURMALINE-MM1

RId vs Rd4

0.69

(0.57-0.83)

0.73

(0.60-0.89)

0.74

(0.59-0.94)

87% 79% 78%

70% 33% 48%

32% 4% 14%

28.6 20.7 20.5

0.79

(0.63-0.99)

0.77

(0.61-0.97)NE

K, carfilzomib; E, elotuzumab; N, ixazomib.

53

Key eligibility criteria • RRMM with measurable disease

• ≥2 prior lines of treatment

• Not received anti-CD38 therapy

PAVO: Study Design; ASH 2016Phase 1b, open-label, multicenter, dose-finding, proof of concept study

RRMM, relapsed or refractory multiple myeloma; QW, weekly; Q2W, every 2 weeks; Q4W, every 4 weeks; Ctrough, trough concentration; ORR, overall response rate; CR, complete

response;

PK, pharmacokinetics. aGroup 2 comprises 4 distinct cohorts, each treated with DARA 1,800 mg and rHuPH20 45,000 U. Ctrough on Cycle 3/Day 1 in Group 1 supported dose selection for Group 2.

The study evaluation team reviewed safety after Cycle 1 and PK after Cycle 3/Day 1 for each group.bAdministered 1 hour prior to infusion.

Group 1 (n = 8)

DARA: 1,200 mg

rHuPH20: 30,000 U

Group 2a (n = 45)

DARA: 1,800 mg

rHuPH20: 45,000 U

Dosing schedule

Approved schedule for IV

1 Cycle = 28 days

Infusion time

1,200 mg: 20-min infusion (60 mL)

1,800 mg: 30-min infusion (90 mL)

Pre-b/post-infusion medication

Acetaminophen,

diphenhydramine, montelukast,

and methylprednisolone

Primary endpoints• Ctrough of DARA at

Cycle 3/Day 1

• Safety

Secondary endpoints• ORR

• CR

• Duration of response

• Time to response

54

1/6/2017

28

IRRs: ASH 2016

1,200 mg

n = 8

1,800 mg

n = 45

IRR, % (n) 13 (1) 24 (11)

Chills 13 (1) 9 (4)

Pyrexia 0 (0) 9 (4)

Pruritus 0 (0) 4 (2)

Dyspnea 13 (1) 0 (0)

Flushing 0 (0) 2 (1)

Hypertension 0 (0) 2 (1)

Hypotension 0 (0) 2 (1)

Nausea 0 (0) 2 (1)

Non-cardiac chest pain 13 (1) 0 (0)

Oropharyngeal pain 0 (0) 2 (1)

Paresthesia 0 (0) 2 (1)

Rash 0 (0) 2 (1)

Sinus headache 0 (0) 2 (1)

Tongue edema 0 (0) 2 (1)

Vomiting 0 (0) 2 (1)

Wheezing 0 (0) 2 (1)

All IRRs in the 1,800-mg

group were grade 1 or 2

One grade 3 IRR of

dyspnea in the 1,200-mg

group

No grade 4 IRRs were

observed

All IRRs occurred during

or within 4 hours of the

first infusion

No IRRs occurred during

subsequent infusions in

either group

Abdominal wall SC

injections were well

tolerated

Low IRR incidence and severity with DARA SC 55

Dose Mean (SD) Profiles; ASH 2016

Normal time after 1st dose (hours)

1st dose mean

Normal time after 8th dose (hours)

8th dose mean

DA

RA

mean s

eru

m c

oncentr

ation (

µg

/mL)

0

400

900

1,200

1,600

2 24 72 168

1,200 mg SC (n = 5a)

1,800 mg SC (n = 42a)

16 mg/kg IV (n = 2a,c)

100

200

300

500

600

700

800

1,000

1,100

1,400

10

DA

RA

mean s

eru

m c

oncentr

ation

(µg

/mL)

–40

200

280

400

2 24 72 168

1,200 mg SC (n = 8a)

1,800 mg SC (n = 44a)

16 mg/kg IV (n = 20a,b)

0

80

120

160

240

10 12 48

360

320

40

PK for 1,800 mg SC dose is consistent with the 16 mg/kg IV dose,

with comparable Ctrough and variability

SD, standard deviation.aNumber of patients with full PK profile at pre-dose.bFrom study GEN501 Part 2.cFrom study GEN501 Part 1.

56

1/6/2017

29

Simulation of Mean Concentration-Time Profiles of DARA Following SC and IV Dosinga

Similar Cmax for SC 1,800 mg versus IV 16 mg/kg overall

Lower Cmax for SC 1,800 mg during the initial weekly administration

Higher Ctrough for SC 1,800 mg versus SC 1,200 mgCmax, peak plasma concentration. aDosing schedule is QW in Cycles 1 to 2, Q2W in Cycles 3 to 6, and Q4W thereafter.

Co

nc

en

tra

tio

n (

µg

/mL

)

800

600

400

200

0

0

Time (h)

2,500 5,000 7,500

IV 16 mg/kg

SC 1,200 mg

SC 1,800 mg

57

ORR

Responses to DARA-PH20 were observed across both groups

Response-evaluable set.

sCR, stringent complete response; VGPR, very good partial response; PR, partial response; MR, minimal response; SD, stable disease; PD, progressive disease.

2529

7

2

0

5

10

15

20

25

30

35

40

1,200 mg(n = 8)

1,800 mg(n = 45)

OR

R (

%)

sCR

VGPR

PR

ORR = 25%

ORR = 38%

≥VGPR:

9%

Response1,200 mg

n = 8

1,800 mg

n = 45

ORR, % (n)

sCR

CR

VGPR

PR

MR

SD

PD

25 (2)

0 (0)

0 (0)

0 (0)

25 (2)

13 (1)

50 (4)

13 (1)

38 (17)

2 (1)

0 (0)

7 (3)

29 (13)

11 (5)

38 (17)

13 (6)

Deeper responses were observed in the 1,800-mg group

58

1/6/2017

30

Conclusions: ASH 2016

DARA can be combined safely with rHuPH20

SC DARA was well tolerated with low IRR rates

– SC injections were well tolerated

PK profile of the 1,800-mg dose was consistent with

DARA 16 mg/kg IV

Efficacy was consistent with IV DARA in a similar patient

population

– 38% ORR, including deep responses (1 sCR)

Tolerability, safety, and PK data support continued development

of SC DARA in different settings

59

Malavasi F et al. Physiol Rev. 2008 Jul;88(3):841-86.

Is there a role for ectoenzymes in this intricate network?

BM contains a panel of growth-permissive and restrictivesignals from the tumor microenvironment. These signalslikely co-evolve with the tumor. (M.V. Dhodapkar, Blood 2016)

60

1/6/2017

31

ASH 2016 – ISA POM DEX (Richardson PG et al.) Introduction

Modes of action of isatuximab

ADCC/CP, antibody-dependent cellular cytotoxicity/phagocytosis; CDC, complement-dependent cytotoxicity; Mφ, macrophage; MDSC, myeloid-derived suppressor cell; NK, natural killer cell.

61

Results: Paraprotein reduction

• Reductions in paraprotein levels were recorded in the majority of patients.

Waterfall plot of best percentage change in paraprotein levels

Post-baseline paraprotein data were not available for one patient in the 5 mg/kg cohort.QW, weekly; Q2W, once every 2 weeks. 62

1/6/2017

32

Results: Time on treatment

• Seven patients who achieved at least PR remained on treatment at data cutoff.

Time on treatment by best confirmed response (at least PR)

CR, complete response; PR, partial response; QW, weekly; Q2W, once every 2 weeks; VGPR, very good partial response.

63

Summary

• The combination of isatuximab with Pom/Dex is generally well tolerated in patients with RRMM.o The AEs observed are generally consistent with the known safety profiles of the

individual agents.

• IARs were all Gr 1/2 in intensity and tended to occur with the first infusion.

• The PK parameters of isatuximab do not appear to be affected by Pom/Dex co-administration.

• The combination of isatuximab with Pom/Dex was clinically active in this heavily pretreated patient population.

• Confirmed ORR was 64%; confirmed ORR with isatuximab 10 mg/kg was 67%.• Confirmed ORR in IMiD-refractory patients was 64%.

• The MTD for this combination was not reached at the highest isatuximab dose level tested; 10 mg/kg was the selected dose for the expansion cohort based on these preliminary clinical, efficacy, safety, and PK data.

• A global Phase III study of isatuximab plus Pom/Dex is planned to start in 2016.

64

1/6/2017

33

Anti-CD38 antibody-mediated therapy in myeloma:

some unbeaten paths of potential application

(ASH 2016, Malavasi F et al.)

1) Can the enzymatic activities exerted by CD38

play a role in these events?

2) Does the enzymatic activities of CD38

collaborate with other ectoenzymes in the bone

marrow niche?

3) Do therapeutic anti-CD38 antibodies interfere

with the enzymatic activities ruled by CD38?

4) Do the products derived from the ectoenzymes

operate outside the niche?

65

First in Human Study with GSK2857916,

An Antibody Drug Conjugated to Microtubule-disrupting

Agent Directed Against B-cell Maturation Antigen, in Patients

with Relapsed/Refractory Multiple Myeloma:

Results from Study BMA117159 Part 1 Dose Escalation

ASH 2016

Adam D. Cohen1, Rakesh Popat2, Suzanne Trudel3, Paul G. Richardson4,

Edward N. Libby5, Nikoletta Lendvai6, Larry D. Anderson Jr7 , Heather J. Sutherland8,

Daren Austin9, Stephen DeWall9, Catherine E. Ellis9, Zangdong He9, Jolly Mazumdar9,

Catherine Wang9, Joanna Opalinska9, Peter M. Voorhees10

1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; 2University College London Hospitals

NHS Foundation Trust, London, UK; 3Princess Margaret Cancer Centre, Toronto, ON, Canada; 4Dana-Farber Cancer

Institute, Boston, MA, USA; 5Seattle Cancer Care Alliance, Seattle, WA, USA; 6Memorial Sloan-Kettering Cancer Center, New

York, NY, USA; 7University of Texas Southwestern, Dallas, TX, USA; 8Vancouver General Hospital, Vancouver, BC, Canada; 9GlaxoSmithKline, USA/UK; 10 Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA

66

1/6/2017

34

BCMA

Effector

Cell

Mechanisms of Action:

1. ADC mechanism

2. ADCC mechanism

3. Immunogenic cell death

4. BCMA receptor signalling

inhibition

x

BCMA

BCMA

BCMA

GSK2857916

Lysosome

Fc

Receptor

ADCC

ADC

Cell death

Malignant

Plasma

Cell

Background

– BCMA expression is restricted to B cells

at later stages of differentiation and is

requisite for the survival of long lived

plasma cells

– BCMA is broadly expressed at variable

levels on malignant plasma cells

– GSK2857916 is a humanized,

afucosylated IgG1 anti-BCMA antibody

conjugated to a microtubule disrupting

agent MMAF via a stable, protease

resistant maleimidocaproyl linker

– Preclinical studies demonstrate its

selective and potent activity1

– Target specific

– Enhanced ADCC

Fc region of

the Antibody

– Stable in

circulationLinker

– MMAF (non cell

permeable, highly

potent auristatin

Drug

ADC, antibody-drug conjugate; ADCC, antibody-dependent cell-mediated cytotoxicity;

BCMA, B-cell maturation antigen; Fc, Fragment crystallizable; IgG, immunoglobulin G;

MMAF, monomethyl auristatin-F1Tai YT, et al. Blood 2014;123(20):3128-38.

67

Maximum % Change in M-Protein or Free Light Chain

CBR, clinical benefit rate; CI, confidence interval; FLC, free light chain; M-protein, myeloma protein; MR, minimal response;

ORR, overall response rate; PD, progressive disease; PR, partial response; sCR, stringent complete response; SD, stable

disease; VGPR, very good partial response

ORR = 8/30 (27%; 95% CI: 12.3%, 45.9%)

•1 sCR, 3 VGPR, 4 PR

CBR = 11/30 (37%; 95% CI: 19.9%,

56.1%)

-25

-50

25

0

200

175

150

125

100

75

50

-75

-100

0.9

6 (

PD

)

0.9

6 (

PD

)

0.0

6 (

SD

)

0.1

2 (

PD

)

0.4

8 (

SD

)

0.1

2 (

PD

)

0.1

2 (

SD

)

0.1

2 (

PD

)

0.2

4 (

SD

)

0.4

8 (

SD

)

1.9

2 (

SD

)

4.6

0 (

SD

)

4.6

0 (

SD

)

1.9

2 (

SD

)

1.9

2 (

MR

)

0.2

4 (

MR

)

4.6

0 (

MR

)

4.6

0 (

PR

)

4.6

0 (

PR

)

3.4

0 (

PR

)

0.9

6 (

PR

)

4.6

0 (

VG

PR

)

3.4

0 (

VG

PR

)

3.4

0 (

sC

R)

1.9

2 (

VG

PR

)

Serum M-Protein

Urine M-Protein

Serum FLC

Dose, mg/kg (best unconfirmed response)

Ma

xim

um

pe

rce

nta

ge

ch

an

ge

fro

m b

ase

lin

e

68

1/6/2017

35

*

Patient ongoing

Patient completed 16 cycles

Part 1: Summary of Clinical Activity and Duration on Study

40 60 100 1400 1601208020 340320300280260240220200180 360

PDSD

PDPDSDPD

MissingMissing

SDMR

MissingMissing

SDSD

PDPD

PRSD

SDMR

VGPRsCR

VGPRPR

SDPR

MRVGPR

PRSD

0.03 mg/kg

0.06 mg/kg

0.12 mg/kg

0.24 mg/kg

0.48 mg/kg

0.96 mg/kg

1.92 mg/kg

3.40 mg/kg

4.60 mg/kg

Study treatment duration (days)

Pa

tie

nts

6 months

≤1.92 mg/kg, n=21

ORR=9.5%

≥3.4 mg/kg, n=9

ORR= 66.7%

Cycle 8:

increased to 0.48

Cycle 13:

increased to 0.96

*

69

Conclusions

– GSK2857916 was well tolerated with no DLTs up to 4.6 mg/kg q3w; MTD was not

reached

– AEs were manageable with ocular toxicity emerging as the most frequent reason for

dose modifications

– Hematologic toxicities such as thrombocytopenia and anemia are expected in the

disease under study

– Thrombocytopenia emerged more frequently as treatment-related at higher doses; although

events were transient and manageable

– 66.7% ORR including a stringent CR observed at higher doses of GSK2857916 in

this refractory population

– 3.4 mg/kg was selected as the dose to investigate in the expansion phase of the

study based on the totality of the data from Part 1

– Pharmacodynamic and correlative analyses are ongoing

70

1/6/2017

36

Immune Suppressive Microenvironment in MM

NKB

NKT

CD4

CD8

pDC, MDSC induced

immune suppression

MM

MMMM

Stroma

IL-6, IL-10, TGFβ, PGE,

ARG1, NO, ROS, COX2

Depletion of cysteine

MM induced

immune

suppression

Tumor promotion and

induction of PD-L1

expression

MMPD1PD-L1

PD1TregPD1

PD-L1

TAMPD-L1

MDSCPD-L1

PD1PD1

pDC

Görgün GT, et al. Blood 2013;121:2975-87 71

Lesokhin, A wt al. Blood 2014, 124, 291

Phase I study of Nivolumab in patients with

relapsed or refractory lymphoid malignanciesPreliminary Results

72

1/6/2017

37

Lenalidomide enhances checkpoint blockade-

induced multiple myeloma cytotoxicity

Güllü Görgün et al. Clin Cancer Res 2015;21:4607-4618 73

Pembrolizumab and the PD-1 Pathway

• The PD-1 pathway is often exploited by tumors to evade immune surveillance1-3

• Role of PD-1 inhibitors in MM1-2

• Pembrolizumab blocks interaction between PD-1 and PD-L1/PD-L24-6

• Rationale for the combination of IMiDs and PD-L1 blockade7

– Lenalidomide reduces PD-L1 and PD-1 expression on MM cells and T- and myeloid- derived suppressor cells

– Lenalidomide enhances checkpoint blockade–induced effector cytokine production in MM bone marrow and induced cytotoxicity against MM cells

1. Liu J et al. Blood. 2007;110:296. 2. Tamura H et al. Leukemia. 2013;27:464. 3. Paiva B et al. Leukemia. 2015;29:2110.4. Keir ME et al. Annu Rev Immunol. 2008;26:677. 5. Hallett WH et al. Biol Blood Marrow Transplant. 2011;17:1133. 6. Homet Moreno B, Ribas A. Br J Cancer. 2015;112:1421. 7. Görgün G et al. Clin Cancer Res. 2015;21:4607.

74

1/6/2017

38

Mehmet Kocoglu and Ashraf Badros Pharmaceuticals 2016, 9(1), 3

Ongoing Clinical Trials Evaluating Checkpoint blockade

in Combination with IMiD in Myeloma

75

Pembrolizumab + REV/DEX

• Patients had heavily pretreated RRMM (median four prior therapies); 86% had received a stem cell transplant and 75% were refractory to lenalidomide

– 49% were unresponsive to two, three, or four medications

• Acceptable safety profile, with AEs similar to those seen in patients using pembrolizumab in solid tumors

• ORR was 50% and disease control rate (CR, PR, or SD) was 98%

Mateos M-V et al. J Clin Oncol. 2016;34(suppl):abstr 8010.

NCT02036502.

Conclusion: results are promising; phase 3 studies of pembrolizumab are now under way.

76

1/6/2017

39

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for RR MM

Badros et al UMD ASH 2016

• Phase II study of 48 pts

– Pembro 200 mg Q 2 weeks Pom 4 mg Q21 Dex40mg QW

– Median of 3 prior lines, 80% double refractory

– High risk cytogenetics 38%

– Interstitial pneumonitis 13%; hypothyroid 10%

– ORR 56%; sCR 8%; VGPR 13%; PR 29%

– Double refractory ORR: 55%

– Median DOR for responding patients: 8.8 months77

Siegel DS et al. J Clin Oncol. 2016; Abstract TPS8072.

Richardson PG et al. ASH 2016, MMRF Symposium

ASH 2016: Durvalumab in MM –Combos with DARA, POM , DEX

Durvalumab: Hypothesized Mechanism of Action

Reprinted from Ibrahim R et al. Semin Oncol. 2015;42(3):474-483, Copyright 2015.

78

1/6/2017

40

Harnessing the Immune System to Fight Myeloma:

Passive Active

Monoclonal antibodies

Chimeric antigen receptor (CAR) T cells

Vaccines (therapeutic not preventive)

Types of Immunotherapy, Immuno-Oncology

Direct effects

CDC

Cell death

ADCC

NK cell

Myeloma cellFc receptor

LysisMAC

C1q

Antigen

Monoclonal antibody

3. Infuse MM-targeted cells back to

patient

2. Modify andexpand cells

in lab

1. Extract WBCsfrom patient

Richardson PG et al, ASH 2016 79

Myeloma CAR therapy

ASH 2015- 2016

• Multiple promising targets:

• CD19, CD138, CD38, CD56, kappa, Lewis Y, CD44v6, CS1 (SLAMF7), BCMA

• Functional CAR T cells can be generated from MM patients

• CAR T and NK cells have in vitro and in vivo activity against MM

• Clinical trials underway

• Anecdotal prolonged responses but no robust efficacy data available yet

• Many questions remain about CAR design:

• optimal co-stimulatory domains

• optimal vector

• optimal dose and schedule

• need for chemotherapy

• Perhaps ‘cocktails’ of multiple CARs or CARs + chemotherapy will be

required for best outcomes80

1/6/2017

41

MM Pt #1: Response to CD19 CAR Therapy

Additionalregimensincluding…

- carfilzomib- pomalidomide- vorinostat- elotuzomab

CD138 CD138

CTL019 first undetectableMRD-negative

>> sCR, MRD neg

>> D +307 (per paper)

>> TTP after ASCT #1 D+190

>> Remission inversion

>> Relapsed after 1 yr – now

in response to DARAGarfall et al, NEJM 2015; 373: 1040-7 81

82

1/6/2017

42

83

84

1/6/2017

43

85

86

1/6/2017

44

87

Integration and Impact of

Novel Agents, including Immune Therapies

• Innovations (PIs, IMiDs) to date have produced significant improvements in

PFS and OS: recent approvals (e.g. Carfilzomib, Ixazomib) will augment this

• Next wave of therapies….. crucially, agnostic to mutational thrust?

• Baseline immune function appears to also be a key barrier to success but

may be targetable (e.g. use of PD1/PDL1 blockade)

• MoAbs (Elo, DARA, ISA) have activity in high risk disease, represent true

new novel mechanisms, as well as other immuno-therapeutics (e.g.

checkpoint inhibitors, vaccines)

• New insights to mechanisms of drug action (e.g. AC 241) are further

expanding therapeutic opportunities with combinations

• Numerous other small molecule inhibitors show promise (e.g. HDACi’s,

CXCR4, BCL, AKT, CDK, HSP 90, Nuclear Transport, KSP, BET bromodomain

proteins/Myc, DUBs, MEK)

• Further refinement of prognostics and MRD will guide therapy88

1/6/2017

45

Continuing Evolution of Multiple Myeloma Treatment:

Selected New Classes and Targets 2016

IMiD, immunomodulatory drug;

HDAC, histone deacetylase

*Not yet FDA-approved for MM;

available in clinical trials

1st Generation Novel Agents 2nd Generation Novel Therapies/ Immunotherapy

Chemotherapy

Monoclonal antibody

Proteasome inhibitor

IMiD HDAC inhibitor

20122003 2006

Bortezomib + Doxil

2007 2013 2015

Carfilzomib

Bortezomib

Thalidomide

Lenalidomide

Pomalidomide

Panobinostat

2016+

ElotuzumabIsatuximab*

CAR-T*

Adoptive T cell therapy

Vaccines

Atezolizumab*Durvalumab*

Nivolumab*Pembrolizumab*

Checkpoint inhibitors

Vaccines*

Ixazomib

Daratumumab

AC-241/1215*

Marizomib*

3rd Generation IMiDs*

Melflufen*

89

Academia

FDA

EMEA

NIH

NCI

Advocacy

MMRF/C;IMF

IMWG;

IMS

Pharmaceuticals

Ongoing MM Collaborative Model for Rapid

Translation From Bench to Bedside

Progress and

Hope

19 new FDA-

approved

drugs/combos/

indications in

last 13 yrs90

1/6/2017

46

The Impact Of Novel Therapies

in MM ~ 20162009 –

Patient DG, age 62 years

High Risk IgG kappa MM

DSS 3, ISS 2,

Elevated LDH

17 del positive ,

13 del positive (by FISH) PMH – HTN, nil else.

RD + Zometa => RVD (VGPR) Well tolerated, minimal PN (G1)

2010 ASCT (CY – HDM) (CR)

R/Z maintenance

2011 PD – RVD (PR)

2012 PD – PomVD (VGPR)

2013 PD (aggressive relapse with extra-medullary disease) DARA [501] 16 mg/kg

(CR) to present (> 3 years) “Best I have ever felt since prior to diagnosis”91

Thank YOU!!

Slide Courtesy of Phil McCarthy MD

92

1/6/2017

47

Q&A SessionAsk a question by phone:

• Press star (*) then the number 1 on your keypad.

Ask a question by web:• Click “Ask a question”

• Type your question

• Click “Submit”

Due to time constraints, we can only take one question per person. Once

you’ve asked your question, the operator will transfer you back into the

audience line.

93

Emerging Therapies for Multiple Myeloma:

2016 ASH® Annual Meeting Highlights

• Online chats: Online moderated chat forums: www.LLS.org/chat

• What to ask: Questions to ask your treatment team: www.LLS.org/whattoask

• Free education materials: www.LLS.org/booklets

• Past myeloma education programs: www.LLS.org/programs

• Information Resource Center: Speak one-on-one with an Information Specialist who can assist you

through cancer treatment, financial, and social challenges.

EMAIL: infocenter@LLS.org

TOLL-FREE PHONE: (800) 955- 4572

94

Emerging Therapies for Multiple Myeloma:

2016 ASH® Annual Meeting Highlights